Published • loading... • Updated
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
Kelun-Biotech says both studies showed strong response rates, including a 70.2% objective response rate for sac-TMT plus pembrolizumab.
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. will present two registrational studies at the American Society of Clinical Oncology Annual Meeting in Chicago on May 29, 2026, featuring sac-TMT and lunbotinib lung cancer data.
- The Phase III OptiTROP-Lung05 trial enrolled 413 patients with previously untreated, PD-L1 positive advanced NSCLC without EGFR or ALK alterations; as of October 29, 2025, follow-up data showed 71 pre-treated and 92 treatment-naive patients.
- Sac-TMT plus pembrolizumab achieved 70.2% objective response rate versus 42.0% for pembrolizumab alone, with a 0.35 hazard ratio for progression-free survival ; pre-treated patients reached 87.1% ORR with 27.5-month median PFS.
- Lunbotinib fumarate demonstrated manageable tolerability with grade 3 or higher adverse events in 40.5% of patients and only 1.2% permanent discontinuations; the NMPA accepted its new drug application for RET fusion-positive NSCLC.
- Through a May 2022 agreement with MSD covering all territories outside Greater China, Kelun-Biotech's sac-TMT is under evaluation in 17 global Phase III studies; the company currently advances more than 30 innovative drug projects with 4 approved.
Insights by Ground AI
35 Articles
35 Articles
Bennington Banner+32 Reposted by 32 other sources
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
Sacituzumab tirumotecan (sac-TMT)(佳泰莱®) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced NSCLC: Results from the randomized, controlled, registrational Phase III OptiTROP-Lung05 study (Abstract #8506)Efficacy and safety of lunbotinib fumarate (A400/EP0031,宁泰莱®[1]), a next-generation selective RET inhibitor (SRI), from…
Merck partner Kelun outlines Phase 3 lung cancer success in China study
Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug conjugate sac-TMT, raising hopes that the benefit could translate to Western patients. Patients who ...
Coverage Details
Total News Sources35
Leaning Left5Leaning Right3Center15Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
L 22%
C 65%
13%
Factuality
To view factuality data please Upgrade to Premium
